 |
|
|
| |
The Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF ("Quad") Compared to Efavirenz/Emtricitabine/Tenofovir DF in Treatment Naïve HIV-1 Infected Subjects: Primary Results of Study GS-US-236-0102
|
| |
| |
Jules Levin
19th Conference on Retroviruses and Opportunistic Infections
March 7, 2012
Paul Sax1, Edwin DeJesus2, Anthony Mills3, Andrew Zolopa4, Calvin Cohen5, David Wohl6, Joel Gallant7, Hui C Liu8, Kirsten White8, Erin Quirk8, and Brian Kearney8
1Brigham and Women's Hospital, Harvard Medical School, Boston, MA, US; 2Orlando Immunology Center, Orlando, FL, US; 3Anthony Mills MD, Inc., Los Angeles, US; 4Stanford University, Palo Alto, CA, US; 5Community Research Initiative of New England, Boston, MA, US; 6University of North Carolina, Chapel Hill, NC, US; 7Johns Hopkins School of Medicine, Baltimore, MD, US; 8Gilead Sciences, Foster City, CA, US
|
| |
|
|
|
|
|
